Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome

Abstract

Objective

To evaluate the effectiveness of bromocriptine for prevention of ovarian hyperstimulation syndrome (OHSS).

Methods

The retrospective study included women at risk of OHSS who were receiving gonadotropin‐releasing hormone antagonist protocols, including 52 women given 2.5 mg bromocriptine by rectal insertion, 52 women given 500 ml intravenous hydroxyethyl starch (HES), and 40 women who received no intervention. Treatments were administered daily for 5 days beginning on the day of oocyte retrieval. Baseline information and data related to OHSS were compared.

Results

No significant differences were found among groups in estradiol concentration on the day of trigger or in number of retrieved oocytes. Incidence of mild OHSS was not significantly different among groups, respectively 13.5%, 15.4%, and 17.5% ( P > 0.05). The incidence of moderate to severe OHSS was significantly lower in the bromocriptine and HES groups compared with the control group, respectively 7.7%, 5.8%, and 22.5% ( P < 0.05). D‐dimer levels were significantly lower in the bromocriptine and HES groups compared with the control group on Day 5 after oocyte retrieval ( P < 0.05). No differences in liver or renal function were found in the three groups.

Conclusion

Bromocriptine was apparently as effective as intravenous HES in patients with high risk of OHSS.

Synopsis

Prophylactic rectal administration of bromocriptine showed similar effects to intravenous hydroxyethyl starch in patients with high risk of ovarian hyperstimulation syndrome.